Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most symptom and risk-framing statements are consistent with the provided label excerpts (notably OHSS, monitoring, and multiple births). However, several specific assertions (e.g., vomiting, fatigue, and particular allergic reaction manifestations including trouble breathing and severe dizziness/fainting) are not explicitly supported by the provided label text, and there are missing details required for precise safety communication (e.g., follow-up duration after hCG, and that contraindications include pregnancy).
Category Scores
Accurate Statements
Ovidrel (choriogonadotropin alfa; hCG) is used to trigger ovulation.
Supported by Label Section 1 (induction of ovulation) and Label Section 2 (OI administration).
Ovidrel can cause injection-site reactions including pain, redness, and swelling.
Supported by Label Section 6 examples: application site disorders and injection site pain (explicitly 'injection site pain'; redness/swelling not explicitly stated).
More serious risks associated with Ovidrel are linked to ovarian stimulation.
Supported by Label Section 5 emphasizing overstimulation/OHSS risk after hCG therapy.
More serious risks associated with Ovidrel may occur especially if the dose is too high.
Supported by Label Section 5 clinical trial data showing higher OHSS incidence at 500 mcg vs 250 mcg.
More serious risks associated with Ovidrel may occur in patients with risk factors for ovarian hyperstimulation syndrome (OHSS).
Supported by Label Section 5: Ovidrel is capable of causing OHSS in women 'with or without pulmonary or vascular complications' and discusses risk consideration; risk-factor language for OHSS is referenced via clinical concept of risk factors.
OHSS (ovarian hyperstimulation syndrome) is an important side effect to watch for after hCG trigger injections.
Supported by Label Section 5 (explicit OHSS warning and need for monitoring/follow-up).
OHSS can range from mild to life-threatening.
Partially supported by Label Section 5 distinguishing 'mild to moderate uncomplicated ovarian enlargement' vs 'Severe OHSS may progress rapidly ... to become a serious medical event' (life-threatening wording not explicitly present).
Symptoms of OHSS may include rapid weight gain.
Not explicitly supported by the provided label excerpts (no specific symptom list provided in excerpts).
Symptoms of OHSS may include a swollen or distended abdomen.
Supported indirectly by Label Section 5: ovarian enlargement 'may be accompanied by abdominal distention and/or abdominal pain' (OHSS symptom phrasing not explicitly tied, but distention is present).
Symptoms of OHSS may include severe pelvic or abdominal pain.
Not explicitly supported by the provided label excerpts (no explicit pelvic/abdominal pain symptom list for OHSS in excerpts).
Symptoms of OHSS may include nausea and vomiting that do not improve.
Partially supported by Label Section 6 (Nausea reported as an adverse event example) but not supported as an OHSS-specific 'nausea and vomiting that do not improve' construct.
Allergic reactions can occur with Ovidrel.
Not explicitly supported by provided label excerpts.
Ovidrel can increase the chance of multiple pregnancy when used to trigger ovulation.
Supported by Label Section 5 'Multiple Births' describing reports of multiple births associated with Ovidrel treatment and advising potential risk.
The chance of multiple pregnancy depends on follicle development.
Not explicitly supported by provided label excerpts (no explicit linkage stated).
The chance of multiple pregnancy depends on how many eggs are released.
Not explicitly supported by provided label excerpts (no explicit linkage stated).
Multiple pregnancy is described as a risk because the medication helps stimulate ovulation.
Supported at a high level by Label Section 5 associating multiple births with Ovidrel treatment and Label Section 1/12 describing induction of ovulation; direct causal phrasing is not exact.
The likelihood and severity of side effects like OHSS depend on how many follicles or eggs developed before the trigger shot.
Supported by Label Section 2: withholding administration in 'excessive ovarian response' evidenced by multiple follicular development; and Label Section 5: careful monitoring of ovarian response.
The likelihood and severity of side effects like OHSS depend on previous history of OHSS.
Not explicitly supported by provided label excerpts (some risk-factor discussion exists, but prior OHSS history is not explicitly stated).
The likelihood and severity of side effects like OHSS depend on PCOS or other conditions that increase ovarian response.
Not explicitly supported by provided label excerpts (risk-factor framework exists, but PCOS not mentioned in excerpts).
The likelihood and severity of side effects like OHSS depend on other fertility medications used alongside Ovidrel.
Not explicitly supported by provided label excerpts (label references ART/OI programs and FSH pretreatment, but does not state this specific dependency on 'other fertility medications' beyond context).
Unsupported Statements
Ovidrel can cause headache.
Not explicitly supported by the provided label excerpts (no headache adverse reaction text included).
Ovidrel can cause nausea.
Label Section 6 includes 'Nausea (ART): 3.4%' as an example adverse event; however, the claim is generally correct. If strictly limited to provided excerpts, this is supported.
Ovidrel can cause vomiting.
Not explicitly supported by provided label excerpts.
Ovidrel can cause abdominal bloating or discomfort.
Abdominal distention and/or abdominal pain are mentioned in context of ovarian enlargement (Label Section 5), but 'discomfort' and tying to Ovidrel as a direct claim is not explicitly stated.
Ovidrel can cause injection-site reactions including pain, redness, and swelling.
Injection site pain and application site disorders are supported (Label Section 6), but 'redness' and 'swelling' are not explicitly stated in the provided excerpts.
Ovidrel can cause fatigue.
Not explicitly supported by provided label excerpts.
Symptoms of OHSS may include rapid weight gain.
No such symptom is explicitly listed in the provided label excerpts.
Symptoms of OHSS may include severe pelvic or abdominal pain.
No explicit OHSS symptom list including severe pelvic/abdominal pain is provided in excerpts.
Symptoms of OHSS may include nausea and vomiting that do not improve.
Nausea is present as an adverse event example (Label Section 6), but vomiting and the 'does not improve' phrasing are not supported.
Allergic reactions can occur with Ovidrel.
No allergic reaction statements are present in the provided label excerpts.
Allergic reactions with Ovidrel may include hives, rash, and itching.
Not supported by provided label excerpts.
Allergic reactions with Ovidrel may include facial or lip swelling.
Not supported by provided label excerpts.
Allergic reactions with Ovidrel may include trouble breathing.
Not supported by provided label excerpts.
Allergic reactions with Ovidrel may include severe dizziness or fainting.
Not supported by provided label excerpts.
The chance of multiple pregnancy depends on follicle development.
No explicit statement linking multiple pregnancy probability to follicle development is included in provided excerpts.
The chance of multiple pregnancy depends on how many eggs are released.
No explicit statement linking multiple pregnancy probability to eggs released is included in provided excerpts.
The likelihood and severity of side effects like OHSS depend on a previous history of OHSS.
No explicit statement about prior OHSS history appears in provided excerpts.
The likelihood and severity of side effects like OHSS depend on PCOS or other conditions that increase ovarian response.
PCOS is not mentioned in provided excerpts.
The likelihood and severity of side effects like OHSS depend on other fertility medications used alongside Ovidrel.
No explicit statement provided linking severity to other fertility medications beyond general program context.
Contradictions
Important Omissions
Ovidrel contraindication for pregnancy (Section 4) is not mentioned; related claims about risks after trigger do not include pregnancy contraindication context.
Importance:
Moderate
Label-required monitoring and withholding guidance: administration should be withheld if there is excessive ovarian response, with monitoring using serum estradiol and vaginal ultrasound, and follow-up for at least two weeks after hCG administration (Section 5).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements about specific OHSS/allergic reaction manifestations are not supported by the provided label excerpts, and key label monitoring/withholding instructions and pregnancy contraindication context are omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple symptom and allergic reaction details are not explicitly supported by the provided label excerpts, and key monitoring/withholding guidance is omitted.
Suggested Improvement
Limit adverse reaction/symptom listings to those explicitly present in the provided label text (or clearly cite label sections that list those symptoms), and include the label’s monitoring/withholding requirements (serum estradiol + vaginal ultrasound) and follow-up duration after hCG administration; avoid adding unquoted allergy symptom specifics not present in excerpts.